Cystic fibrosis (CF) is a progressive, life-limiting genetic disorder caused by mutations in the CFTR gene, leading to dysfunctional chloride channels and multisystem involvement. The introduction of CFTR modulators has revolutionized CF management by targeting the underlying protein defect rather than just alleviating symptoms. These therapies such as Ivacaftor, Lumacaftor/Ivacaftor, Tezacaftor/Ivacaftor, and Trikafta have significantly improved outcomes in lung function, nutrition, and quality of life, particularly in patients with specific CFTR mutations. However, most evidence has been derived from adolescent and adult populations, leaving a knowledge gap regarding long-term efficacy and safety in children under 12. This narrative review synthesizes recent evidence, particularly advancements from 2024 to 2025, and compares available modulators with a focus on pediatric populations. It highlights the promising early outcomes of newer therapies like Trikafta and Alyftrek™, while also addressing concerns such as hepatotoxicity, pharmacokinetic variability, access disparities, and limited genotype coverage. Despite promising initial results, the lack of large-scale longitudinal pediatric data remains a significant barrier to fully understanding the enduring benefits and risks of early CFTR modulator therapy. To optimize pediatric CF care, future research must prioritize long-term studies tailored to younger patients, considering growth, organ development, and equitable access to emerging treatments.